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Hepcidin (hepatic bactericidal protein) is a peptide of 20, 22, or 25 amino acids, differing by amino-terminal truncation. It contains 4 intrachain disulfide bonds and 8 cysteine residues (1) (2) (3) . The human hepcidin gene consists of 3 exons and 2 introns. The exons encode an 84 -amino acid prepropeptide containing a typical 24 -amino acid leader peptide at the N-terminus, a 35-amino acid proregion, and the C-terminal 20 -or 25-amino acid peptide (1 ) . Although this peptide was first isolated as a circulating antimicrobial peptide from urine and blood, hepcidin is predominantly expressed and produced by hepatocytes in the liver. Expression is also detectable to a lesser extent in the heart and brain (1 ) . Hepcidin enters the circulation and negatively regulates the export of iron in certain cell populations, most importantly in reticuloendothelial (RE) 4 macrophages (an important site of iron storage) and in duodenal enterocytes (site of dietary iron absorption). Hepcidin does so by binding to the cellular iron exporter ferroportin and inducing its internalization and degradation. Iron retention in RE cell populations acutely lowers circulating iron concentration. The iron retention in enterocytes leads to a decrease in dietary iron absorption. Thus, an increase in hepcidin leads to an increase in RE macrophage iron, decreased dietary iron absorption, and decreased circulating iron, all contributing to anemia. These changes in iron metabolism are typically seen in inflammation (4 ) . Under conditions of inflammation, physiologic regulation of hepcidin is superseded by the upregulatory effects of certain cytokines, most importantly interleukin-6 (IL-6). Binding of Il-6 to its receptor results in phosphorylation of the intracellular signaling molecule STAT3 (signal transducer and activator of transcription 3). Phospho-STAT3 dimerizes and is translocated to the nucleus, where it interacts with a characterized IL-6 response element in the hepcidin promoter (4 ). In oncology patients, anemia of chronic disease due to the underlying cancer is a frequent finding, often aggravated by the myelodepressive effects of chemotherapy. This anemia is characterized by decreased erythrocyte survival, impairment of iron efflux from macrophages and enterocytes, and hyporesponsiveness of erythroid precursors to erythropoietin (5) (6) (7) .
Preclinical and clinical evidence suggests an association between epoetin concentrations and hepcidin as a regulator of the erythroid demand for iron in producing erythrocytes, e.g., injection of epoetin was found to decrease liver hepcidin expression, thus facilitating intestinal iron absorption (8, 9 ) . This association suggests that hypoxia due to anemia acts both on erythropoiesis induction and hepcidin gene downregulation through erythropoietin. The decrease in hepcidin could explain the increased iron release from reticuloendothelial cells and the increased intestinal iron absorption during hypoxia, which increases iron supply for erythropoiesis (9, 10 ) .
About 35%-40% of anemic cancer patients undergoing chemotherapy and treated with epoetins do not respond with an increase in Hb (11 ) . A large part of this hyporesponsiveness is thought to be caused by the decreased availability of iron for the synthesis of hemoglobin caused by inflammatory processes often observed in anemic cancer patients.
Based on a pooled analysis of hepcidin serum concentrations from 5 clinical trials, we aimed to contribute to the understanding of the phenomenon of hyporesponsiveness to epoetin therapy in anemic ironreplete cancer patients.
Our main objective was to assess a potential predictive role of baseline hepcidin concentrations for response to epoetin treatment in anemic cancer patients receiving chemotherapy. This included the identification of an optimized hepcidin cutoff value as a predictive marker for response to epoetin therapy. We sought to analyze the response to epoetin therapy and changes of hepcidin concentrations from baseline to the end of treatment phase in the subgroup of patients with baseline and follow-up hepcidin concentrations.
Materials and Methods

PATIENT POPULATION
Data from 572 patients who had been enrolled in 5 different studies were pooled for our analysis (12) (13) (14) (Y.K. Eid, unpublished report, July 2007; M. Nowrousian, A. Scherhag, and H-U Burger, unpublished report, August 2007). Serum hepcidin concentration at baseline was available in 439 patients. From these patients, only those 408 who were at least 5 weeks in the study have been taken into consideration for analyzing response to epoetin treatment. All five studies were conducted in compliance with the Helsinki Declaration (15 ) . Enrolled patients were anemic cancer patients [hemoglobin (Hb) Յ110 g/L at baseline] who received epoetins for correction of anemia and chemotherapy for the treatment of cancer disease for approximately 12 weeks and stayed at least 5 weeks in the study (Table 1 ). In addition, major inclusion criteria for enrollment of patients in those studies were as follows: male and female adult patients with confirmed diagnosis of cancer, screening transferrin saturation Ͼ20%, WHO performance grade 0 -2, and life expectancy Ͼ6 months. Major exclusion criteria were relevant acute or chronic bleeding, grade 3/4 thrombocytopenia, any erythropoiesis-stimulating therapy within past 3 months, acute infection, or inflammatory disease. In a subgroup of 70 patients from 2 studies, hepcidin concentrations were also measured at study end (end of 12 weeks of therapy) ( Table 1) .
ASSAYS
We assessed hepcidin using an isotope dilution micro-HPLC-tandem MS (MS/MS) method that allows the quantification of hepcidin-25 present at less than nmol/L concentrations (Roche Diagnostics) (16 ) . We measured C-reactive protein (CRP) using the conventional immunoturbidimetric assay method (detection limit Ն3 mg/L). 
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STATISTICAL ANALYSES
The results of this study are derived from the post hoc exploratory analysis of the pooled data set. All analyses were conducted following a predefined statistical plan. The analysis population has been defined as all patients who were in the study for at least 5 weeks and for whom hepcidin concentrations were assessed at baseline. All values, if not indicated otherwise, are reported as mean (SD).
In an attempt to identify an optimal cutoff value of hepcidin, the median value of the analysis population (9.58 nmol/L rounded to 10 nmol/L) was used to separate the patients into low hepcidin and high hepcidin groups. Hb response (defined by 6 criteria, see below) were compared between these 2 groups. Because the results seemed suboptimal with this approach, ROC curves were produced to test various other cutoff hepcidin values. A cutoff of 13 nmol/L turned out to be a better threshold for differentiation and identification of responders and nonresponders in this clinical setting. With the 13 nmol/L cutoff, the ratio of true forecasted responders among the actual responders over the proportion of false forecasted responders among the actual nonresponders was higher than using the median hepcidin value as a cutoff.
Consequently, the analysis population (n ϭ 408) was separated into 2 categories, those individuals whose hepcidin values were above and below 13 nmol/L. We analyzed the effect on several established hemoglobin response criteria. The following 6 response criteria were used for the assessment of response to epoetin therapy:
• Hb rise Ն10 g/L from baseline at least once during 12 weeks of treatment period; • Hb rise Ն20 g/L from baseline at least once during 12 weeks of treatment period; • Hb rise Ն10 g/L at least once from baseline to week 4; • Hb Ն110 g/L at least once during 12-week treatment period; • Hb Ն120 g/L at least once during 12-week treatment period; • Hematopoietic response, defined as Hb increase Ն20 g/L from baseline at least once or Hb Ն120 g/L at least once.
In individuals who received blood transfusions, the hemoglobin values in the 28 days after the transfusion were replaced by the pretransfusion value. We compared response to epoetin therapy between the 2 groups using the 2 test and evaluated the association of baseline hepcidin concentrations and time to response using Kaplan-Meier estimates and log-rank tests.
Results
BASELINE CHARACTERISTICS
Mean (SD) hepcidin concentration at baseline was 5.58 (3.68) nmol/L in the low hepcidin group and 27.9 (17.6) nmol/L in the high hepcidin group ( Table 2 ). The demographic characteristics of patients in the 2 groups, at baseline with respect to age, height, and weight, were well matched. All kinds of epoetin treatments (Aranesp®, NeoRecormon®, Mircera®) were evenly distributed between the 2 hepcidin concentration groups (Table 2) . Mean baseline hepcidin concentrations were lower in patients with lung cancer or solid tumors and higher in patients with hematological tumors ( Table 1 ).
The hemoglobin concentrations at baseline were comparable between the 2 groups. Minor differences between the 2 study groups at baseline were seen with respect to concentrations of CRP: more patients with hepcidin Ͻ13 nmol/L had CRP concentrations Ͻ10 mg/L (51% vs 41%) and more patients with hepcidin Ն13 nmol/L had CRP concentrations Ͼ30 mg/L (30% vs 19%) ( Table 2) . With respect to the stage of underlying disease at baseline, more patients with advanced lung cancer had hepcidin Ͻ13 nmol/L, whereas more patients with multiple myeloma stage 2 and 3 and nonHodgkin lymphoma stage 3 and 4 had hepcidin Ն13 nmol/L (Table 2) .
RESPONSE TO EPOETIN THERAPY BY BASELINE HEPCIDIN
CONCENTRATION
We observed a significantly higher percentage of responders (where response was defined as hemoglobin increase by Ն10 g/L or Ն20 g/L from baseline) in the low hepcidin group and a higher number of nonresponders in the high hepcidin group (P ϭ 0.04 and P ϭ 0.009 for the Ն10 g/L and Ն20 g/L response criteria, respectively). This difference was also statistically highly significant when the response to epoetin treatment was defined as reaching Hb concentration Ն110 g/L and Ն120 g/L (P Ͻ 0.0001 and P Ͻ 0.0001). A statistically significant difference between the 2 groups was also demonstrated when a hematopoietic response was used as a definition for response to erythropoietic therapy (P ϭ 0.0004) ( Table 3 ). The positive predictive value of a baseline hepcidin value Ͻ13 nmol/L to predict an increase of Hb by Ն10 g/L was 77%. No statistical difference was observed when response to epoetin therapy was defined as Hb increase Ն10 g/L in Ͻ4 weeks from baseline (P ϭ 0.6486) ( Table 3) .
Taking into consideration criteria of 10 or 20 g/L of Hb increase from baseline, more responders were observed in study BA16558 (multiple myeloma), where patients had relatively high hepcidin values at baseline, than in study NA17101 (lung cancer), where patients had relatively low values of hepcidin at baseline (Tables 1 and 4) . We compared Kaplan-Meier curves of the time to achieve a response to epoetin therapy (using response criteria of Hb Ն110 g/L, Hb Ն120 g/L, and hematopoietic response) between the low hepcidin and high hepcidin groups. The differences in time to response were highly significant in favor of the low hepcidin concentration groups (P Ͻ 0.0001, P ϭ 0.0003, P ϭ 0.0030, respectively, log rank test) (Fig. 1) .
In the subgroup of 70 patients with solid tumors from 2 studies in which baseline and follow-up hepcidin concentrations were measured, we compared baseline hepcidin concentrations and changes from baseline to the end of the treatment phase in the 59 responders (defined as an increase of Hb by 10 g/L from baseline) vs the nonresponders. Mean (SD) hepcidin concentrations at baseline in responders and nonresponders were 8.26 (8.91) and 12.73 (14.44) nmol/L, respectively ( Table 5 ). The mean hepcidin concentrations in the group of responders did not change significantly during the treatment phase but did increase in the group of nonresponders by 6.54 nmol/L at the end of week 12 (Table 5) .
Discussion
The data presented in this study provide the first analysis of the potential influence of baseline hepcidin concentrations on the response to epoetin therapy and document the changes of hepcidin concentrations over time in anemic cancer patients receiving epoetins for the correction of anemia. Because hyporesponsiveness to epoetins therapy is poorly understood, it would be advantageous to have a biomarker able to identify patients who are not going to respond adequately to epoetin therapy. Inflammation is considered to be one of the most frequent causes of hyporesponsiveness to Hematopoietic response was defined as Hb Ն120 g/L or Hb rise Ն20 g/L from baseline at least once during 12 weeks of treatment. 
Mean (SD)
Responders (n ϭ 59) epoetin therapy (17) (18) (19) (20) . A large part of this hyporesponsiveness to epoetin therapy in cancer patients is thought to be caused by the decreased availability of iron for the synthesis of hemoglobin during inflammatory stages, because the use of endogenous iron and the iron absorption is blocked by upregulated hepcidin (9, 10 ) . With a goal of predicting patients who will respond or not respond adequately to epoetin therapy, we tried to identify a useful hepcidin cutoff for this purpose. As a standard approach when using a continuous dataset, we initially used the median hepcidin value at baseline (9.58 nmol/L rounded to 10 nmol/L) to separate 2 patient groups and then investigated and compared the response to epoetin therapy between these groups. Because results seemed suboptimal with this approach, we produced ROC curves using other cutoff values of hepcidin and found that a threshold of 13 nmol/L turned out to be the best cutoff value for differentiation and identification of responders and nonresponders in this clinical setting.
In our study, patients with low hepcidin concentrations at baseline responded better to epoetin therapy. This was demonstrated by a significantly higher number of responders in the group of patients with low baseline hepcidin concentrations (Ͻ13 nmol/L) when using 5 of 6 Hb response criteria frequently applied to assess efficacy of epoetins. The positive predictive value of baseline hepcidin value below the proposed cutoff value of 13 nmol/L was 77%. Conversely, in the high hepcidin group, a higher number of nonresponders and a low number of responders were observed (Table  3) .
A possible explanation of our findings is the upregulation of circulating IL-6 concentrations and consequent upregulation of hepcidin associated with inflammatory conditions typically observed in many patients with metastatic cancer. Increased IL-6 concentrations have been shown to be a predictor of poor outcome in several solid tumor types (21 ) . An important effect of IL-6 is the activation of hepcidin expression, thereby inhibiting intestinal iron uptake and preventing iron release from macrophages (locking iron) (9, 10 ) . Hepcidin is the key protein involved in the regulation of iron absorption and iron release (9, 10 ) . Furthermore, administration of epoetins may decrease hepcidin concentrations through downregulation of the hepcidin gene (9 ) .
In the context of hepcidin as a marker of inflammation, it should be noted that there was an association between CRP concentrations and baseline hepcidin concentrations in patients with CRP concentrations Ͻ10 mg/L at baseline (Table 2) . Patients with CRP concentrations Ն30 mg/L were equally distributed in the low and high hepcidin groups (46 each) ( Table 2 ).
More analyses are needed to elucidate the correlation between CRP as a marker of inflammation and hepcidin concentrations.
From a clinical perspective, our results suggest that baseline hepcidin concentrations may play a potential role as a predictive marker to identify patients who either are going to respond adequately to epoetin therapy or need to be excluded from anemia correction with epoetins due to a low chance of responding. Commercially available assays for measurement of hepcidin concentrations will enable further research in this area (16, 22, 23 ) .
In the subgroup of 70 patients with baseline and follow-up hepcidin concentrations, only a slight increase of hepcidin from baseline to the end of therapy was observed in patients who responded to epoetin therapy. Conversely, in patients who did not respond to epoetin therapy, an increase of hepcidin by 6.54 nmol/L was seen (Table 5 ). In our view, this finding supports the concept that hepcidin concentrations may also be regulated via metabolic needs for endogenous iron (in our case, e.g., an increased need for iron for hemoglobin synthesis due to epoetin-stimulated erythropoiesis) aiming to increase or decrease iron availability.
LIMITATIONS
The results of our study have several limitations. First, our findings are based on a retrospective analysis of a pooled dataset of patients who were enrolled into 5 different studies that had a primary objective to investigate the response to epoetin therapy and correction of anemia and for whom serum samples for hepcidin measurements were available. The patients enrolled in these studies were admittedly heterogeneous in terms of tumor types and stages, and hence, the hepcidin concentrations would be expected to vary.
Another important limitation of our analyses is that very often cancer progression is associated with inflammatory effects that can upregulate hepcidin concentrations through IL-6 stimulation. It must also be noted that of the 572 patients enrolled in the 5 studies, 185 patients had received at least 1 blood transfusion, a fact that might have confounded the results of analyses of response to epoetin therapy. Some patients enrolled in those studies received iron orally, intramuscularly, or intravenously. Moreover, due to the design of the included studies, neither a placebo nor a control arm could be included in any of our analyses. Finally, our data were derived from a population of cancer patients receiving chemotherapy, and the chosen cutoff of 13 nmol/L for baseline hepcidin concentrations to predict response to epoetin therapy may not be appropriate for other patient populations in other clinical settings.
